サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1796077

鎮咳薬の世界市場

Antitussive Drugs

出版日
ページ情報
英文 372 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
鎮咳薬の世界市場
出版日: 2025年08月22日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 372 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

鎮咳薬の世界市場は2030年までに19億米ドルに達する

2024年に15億米ドルと推定される鎮咳薬の世界市場は、2024～2030年の分析期間においてCAGR 3.6%で成長し、2030年には19億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである末梢作用薬は、CAGR 3.9%を記録し、分析期間終了までに11億米ドルに達すると予想されます。中枢作用薬セグメントの成長率は、分析期間中CAGR 2.6%と推定されます。

米国市場は4億1,630万米ドルと推定、中国はCAGR6.7%で成長予測

米国の鎮咳薬市場は2024年に4億1,630万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.7%として、2030年までに3億7,780万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.8%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界の鎮咳薬市場- 主要動向と促進要因のまとめ

なぜ鎮咳薬が呼吸器ヘルスケア管理の中心なのか？

一般的に咳止めとして知られる鎮咳薬は、咳が続く、または咳が止まらない呼吸器疾患の管理に欠かせない要素となっています。これらの薬剤は、急性上気道感染症、慢性気管支炎、喘息に関連した咳、ある種の肺線維症や肺がんなど、咳が患者の快適さやQOLに大きく影響する疾患に対して特に有効です。鎮咳薬は、脳の咳中枢に作用したり、炎症を起こしている気道を鎮めたりすることで、咳の頻度や強さを軽減します。これらの薬は一般的に、中枢に作用する薬と末梢に作用する薬に分類されます。コデインやデキストロメトルファンなどの中枢作用薬は脳幹レベルで咳反射を抑制するのに対し、末梢作用薬は知覚神経や気道炎症を標的とします。公害、喫煙、季節性ウイルス、慢性疾患などが原因で呼吸器疾患が世界的に増加し続けているため、鎮咳療法による効果的な症状緩和に対する需要が高まっています。さらに、即効性のある症状緩和を求める患者の嗜好や、市販薬での入手のしやすさが、これらの薬剤をさらに普及させ、処方薬と非処方薬の両方の薬箱の常備薬となっています。小児医療や老人医療では、持続する咳が睡眠や栄養の妨げになることがあるため、これらの薬剤は重要な緩和剤にもなっています。鎮咳薬は年齢層や病態を問わず広く使用されていることから、呼吸器ケアの最前線におけるツールとして世界的に重要であることがわかる。

技術革新は鎮咳薬の処方と投与にどのような影響を与えているか？

鎮咳薬の分野における技術革新は、これらの薬剤がどのように製剤化され、送達され、医薬品として広く認識されるかを再定義しています。従来の製剤はシロップや錠剤であることが多いが、現在では徐放性カプセル、溶解可能なストリップ、点鼻スプレー、トローチなどの高度な送達システムによって補完され、より迅速な作用発現や持続的な症状緩和を実現しています。このような技術革新は、特に標準的な経口薬が苦手な小児や高齢者の患者コンプライアンスを向上させることを目的としています。製薬会社はまた、咳反射に関与する特定の神経受容体を標的とする新規活性化合物にも投資しており、コデインのようなオピオイド系鎮咳薬によく見られる眠気、便秘、潜在的依存性などの副作用を最小限に抑えています。ATP感受性カリウムチャネルやTRPV1やP2X3のような感覚ニューロン標的を調節する薬剤など、非オピオイド系の代替薬が臨床試験で有望視されています。これらの新薬の中には、有効な標準治療がない難治性の慢性咳嗽に特化して開発されているものもあります。さらに、薬物動態学の進歩により、より正確な投与レジメンが可能になりつつあり、フレーバーマスキング技術により、特に小児用製剤の嗜好性が改善されつつあります。バイオテクノロジーもまた、神経機能を損なうことなく気道過敏性を低下させる植物性化合物や免疫調節化合物の探索によって貢献しています。これらの継続的な技術革新により、鎮咳療法はより的を絞った、より安全で、より多くの患者が利用できるものとなっています。精密医療と患者中心の医薬品開発が進化を続ける中、鎮咳薬は単なる対症療法としてではなく、呼吸器治療に対するより微妙で個別化されたアプローチの一部として位置づけられています。

規制政策、消費者動向、市場セグメンテーションは鎮咳薬の需要をどのように形成しているか？

鎮咳薬の需要は、規制の枠組み、消費者の嗜好の変化、医薬品市場のセグメンテーションによって大きく形成されます。FDA、EMA、各国の保健機関などの規制機関は、特に有効成分にコデインのような規制物質が含まれる場合、どの製剤が市販薬として販売可能で、どの製剤が処方箋を必要とするかを決定する上で重要な役割を果たしています。近年、オピオイド依存や誤用に対する懸念から、コデイン含有鎮咳薬に対する規制が強化され、より安全な非オピオイド代替薬へのシフトが促されています。これにより、メーカーは製品を改良し、有効性と安全性の両方の基準を満たす革新的な化合物を開発する新たな機会を得た。一方、消費者の行動も市場に影響を与えており、眠くならない、自然な、あるいはハーブベースの治療薬を求める患者が増加しています。この動向は、より広範な栄養補助食品・健康産業における鎮咳薬分野の拡大に拍車をかけており、ハチミツ、ツタ葉エキス、ショウガなどの成分を配合した製品が人気を集めています。さらに、季節や流行病関連の要因によって需要パターンが変化し、COVID-19の大流行時に見られたように、風邪やインフルエンザの季節や呼吸器系ウイルスの流行時に売上が急増します。薬局、eコマース・プラットフォーム、消費者直販チャネルはすべて、在庫と物流能力を強化することで、この変動に適応しています。市場セグメンテーションの観点からは、小児・老年人口には年齢に応じた製剤と投与ガイドラインが必要であり、慢性疾患の患者にはより専門的な介入が求められます。このような重層的でダイナミックな市場環境は、製薬企業が競争力と関連性を維持するために、多様な製品ポートフォリオを開発し、規制基準に適合させ、消費者の期待の変化に対応することを促しています。

鎮咳薬市場の世界的拡大の原動力は？

鎮咳薬市場の成長は、呼吸器系疾患の有病率の上昇、高齢化人口の拡大、汚染レベルの上昇、市販薬の世界の入手のしやすさなど、いくつかの要因が交錯することによって推進されています。最も強力な促進要因の1つは、喘息、慢性気管支炎、COPDなどの慢性呼吸器疾患の発生率の増加であり、これらはすべて慢性的または再発性の咳を伴うことが多いです。これと並行して、インフルエンザ、RSV、風邪などの急性感染症が流行し、即効性の咳止めに対する季節的な需要急増が続いています。特に新興市場における都市化と工業化は、大気汚染と呼吸器過敏症を助長し、対症療法の必要性をさらに高めています。高齢者は免疫力の低下や健康状態の併存により、呼吸器症状の頻度や重症度が高くなる傾向があるため、世界人口の高齢化も大きな役割を果たしています。鎮咳薬は市販されており、流通経路も広く普及しているため、消費者はすぐに医療機関を受診することなく症状を自己管理することができます。製薬会社は、戦略的マーケティング、製品ラインナップの拡大、地域ごとの製品カスタマイズを通じて、このアクセスしやすさを活用しています。研究開発への継続的な投資も、特に慢性咳嗽や治療抵抗性咳嗽の患者に対する治療選択肢を広げています。公衆衛生意識向上キャンペーンや遠隔医療プラットフォームは、早期の症状管理を促し、ひいては薬剤の服用を増加させています。呼吸器の健康が世界の健康問題、特にウイルスの流行後においてますます注目されるようになるにつれて、鎮咳薬市場は、臨床上の必要性と消費者主導の緩和需要の両方に支えられ、着実かつ持続的な成長が見込まれます。

セグメント

薬剤クラス別（末梢に作用する薬剤、中枢に作用する薬剤、その他の薬剤クラス）、剤形別（錠剤、シロップ剤、その他の剤形）、適応症別（疼痛、風邪、咳、その他の適応症）

調査対象企業の例

  • Alkem Laboratories
  • Alembic Pharmaceuticals
  • Amneal Pharmaceuticals
  • Aurobindo Pharma
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Cipla
  • F. Hoffmann-La Roche
  • Glenmark Pharmaceuticals
  • Hikma Pharmaceuticals
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co.
  • Mylan（Viatris）
  • Novartis
  • Pfizer
  • Sanofi
  • Taisho Pharmaceutical
  • Teva Pharmaceutical Industries

AI統合

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38486

Global Antitussive Drugs Market to Reach US$1.9 Billion by 2030

The global market for Antitussive Drugs estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Peripherally Acting Drugs, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Centrally Acting Drugs segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$416.3 Million While China is Forecast to Grow at 6.7% CAGR

The Antitussive Drugs market in the U.S. is estimated at US$416.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$377.8 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Antitussive Drugs Market - Key Trends & Drivers Summarized

Why Are Antitussive Drugs Central to Respiratory Healthcare Management?

Antitussive drugs, commonly known as cough suppressants, have become essential components in the management of respiratory ailments that feature persistent or disruptive coughing as a primary symptom. These medications are particularly relevant for conditions such as acute upper respiratory tract infections, chronic bronchitis, asthma-related coughing, and certain forms of pulmonary fibrosis or lung cancer, where cough significantly affects patient comfort and quality of life. By acting on the cough center in the brain or soothing the irritated airways, antitussive drugs help reduce the frequency and intensity of coughing, which can be physically exhausting, socially disruptive, and even harmful in cases of severe or prolonged episodes. These medications are generally classified into centrally acting and peripherally acting agents. Centrally acting drugs like codeine and dextromethorphan suppress the cough reflex at the level of the brainstem, whereas peripherally acting drugs target the sensory nerves or airway inflammation. As respiratory illnesses continue to rise globally due to pollution, smoking, seasonal viruses, and chronic conditions, the demand for effective symptomatic relief through antitussive therapy is increasing. Additionally, patient preferences for immediate symptom control and over-the-counter accessibility have further popularized these drugs, making them a regular feature in both prescription and non-prescription medicine cabinets. In pediatric and geriatric care, where persistent coughing can interfere with sleep and nutrition, these drugs also offer critical relief. The widespread application of antitussives across age groups and clinical conditions underlines their significance as a frontline tool in respiratory care management worldwide.

How Is Innovation Influencing the Formulation and Delivery of Antitussive Medications?

Innovation in the field of antitussive drugs is redefining how these medications are formulated, delivered, and perceived in the broader pharmaceutical landscape. Traditional formulations, often in the form of syrups and tablets, are now being complemented by advanced delivery systems such as extended-release capsules, dissolvable strips, nasal sprays, and lozenges that provide faster onset of action or sustained symptom relief. These innovations aim to improve patient compliance, particularly among children and elderly individuals who may struggle with standard oral medications. Pharmaceutical companies are also investing in novel active compounds that target specific neural receptors involved in the cough reflex, minimizing side effects such as drowsiness, constipation, or potential dependency that are commonly associated with opioid-based antitussives like codeine. Non-opioid alternatives, including agents that modulate ATP-sensitive potassium channels or sensory neuron targets like TRPV1 and P2X3, are showing promise in clinical trials. Some of these emerging drugs are being developed specifically for refractory chronic cough, a condition that lacks effective standard treatment. Additionally, advances in pharmacokinetics are enabling more precise dosing regimens, while flavor-masking technologies are improving palatability, especially in pediatric formulations. Biotechnology is also contributing by exploring plant-based and immunomodulatory compounds that reduce airway sensitivity without impairing neurological function. These ongoing innovations are making antitussive therapy more targeted, safer, and accessible to a broader patient population. As precision medicine and patient-centric drug development continue to evolve, antitussive drugs are being positioned not just as symptomatic relief tools but as part of a more nuanced and individualized approach to respiratory treatment.

How Do Regulatory Policies, Consumer Trends, and Market Segmentation Shape the Demand for Antitussives?

The demand for antitussive drugs is significantly shaped by regulatory frameworks, evolving consumer preferences, and the segmentation of the pharmaceutical market. Regulatory bodies like the FDA, EMA, and national health agencies play a critical role in determining which formulations can be sold over-the-counter and which require prescriptions, especially when active ingredients involve controlled substances such as codeine. In recent years, concerns about opioid dependency and misuse have led to tighter regulations around codeine-containing cough suppressants, prompting a shift toward safer, non-opioid alternatives. This has opened new opportunities for manufacturers to reformulate products and develop innovative compounds that meet both efficacy and safety benchmarks. Meanwhile, consumer behavior is influencing the market as patients increasingly seek non-drowsy, natural, or herbal-based remedies. This trend has fueled the expansion of the antitussive segment within the broader nutraceutical and wellness industry, with products incorporating ingredients like honey, ivy leaf extract, or ginger gaining popularity. Additionally, seasonal and pandemic-related factors have altered demand patterns, with spikes in sales during cold and flu seasons or respiratory virus outbreaks, as seen during the COVID-19 pandemic. Pharmacies, e-commerce platforms, and direct-to-consumer channels are all adapting to this variability by enhancing their inventory and logistics capabilities. In terms of market segmentation, the pediatric and geriatric populations require age-specific formulations and dosing guidelines, while patients with chronic conditions demand more specialized interventions. This layered and dynamic market environment encourages pharmaceutical companies to develop diverse product portfolios, align with regulatory standards, and respond to shifting consumer expectations in order to remain competitive and relevant.

What Is Fueling the Global Expansion of the Antitussive Drugs Market?

The growth in the antitussive drugs market is driven by several intersecting factors, including the rising prevalence of respiratory illnesses, expanding aging populations, increasing pollution levels, and the global accessibility of over-the-counter medication. One of the most powerful growth drivers is the increasing incidence of chronic respiratory diseases such as asthma, chronic bronchitis, and COPD, all of which often involve chronic or recurrent coughing. In parallel, the spread of acute infections like influenza, RSV, and the common cold continues to generate seasonal demand spikes for fast-acting cough relief. Urbanization and industrialization, particularly in emerging markets, are contributing to air pollution and respiratory hypersensitivity, further amplifying the need for symptomatic treatments. The aging global population also plays a significant role, as older adults tend to experience more frequent and severe respiratory symptoms due to weakened immunity and coexisting health conditions. Over-the-counter availability and widespread distribution channels make antitussive medications easily accessible, allowing consumers to self-manage their symptoms without immediate medical consultation. Pharmaceutical companies are leveraging this accessibility through strategic marketing, broadening product ranges, and regional product customization. Continued investment in research and development is also expanding therapeutic options, particularly for patients with chronic or treatment-resistant coughs. Public health awareness campaigns and telemedicine platforms are encouraging earlier symptom management, which in turn increases medication uptake. As respiratory wellness becomes an increasing focus in global health discussions, especially in the aftermath of viral pandemics, the antitussive drug market is expected to see steady and sustained growth, underpinned by both clinical necessity and consumer-driven demand for relief.

SCOPE OF STUDY:

The report analyzes the Antitussive Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Other Drug Classes); Form (Tablets Form, Syrup Form, Other Forms); Indication (Pain Indication, Cold Indication, Cough Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Alkem Laboratories
  • Alembic Pharmaceuticals
  • Amneal Pharmaceuticals
  • Aurobindo Pharma
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Cipla
  • F. Hoffmann-La Roche
  • Glenmark Pharmaceuticals
  • Hikma Pharmaceuticals
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co.
  • Mylan (Viatris)
  • Novartis
  • Pfizer
  • Sanofi
  • Taisho Pharmaceutical
  • Teva Pharmaceutical Industries

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Antitussive Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Respiratory Infections and Allergies Spurs Demand for Over-the-Counter and Prescription Antitussives
    • Here's How Post-Viral Cough Syndromes, Including Long COVID, Strengthen the Business Case for Extended-Use Cough Suppressants
    • Seasonal Influenza and RSV Surges Throw the Spotlight on Rapid-Acting, Broad-Spectrum Antitussive Therapies
    • Growing Preference for Symptomatic Relief Drives Continued Use of OTC Cough Suppressants in Self-Medication Markets
    • Expansion of Geriatric and Pediatric Populations Sustains Demand for Age-Appropriate, Formulation-Specific Antitussive Drugs
    • Here's the Story: Consumer Shift Toward Natural and Herbal-Based Remedies Unlocks Growth for Plant-Derived Antitussives
    • Concerns Over Opioid Misuse and Abuse Spur Regulatory Scrutiny and Reformulation of Codeine-Based Antitussives
    • Research in Non-Opioid Mechanisms of Action Encourages Innovation in Central and Peripheral Cough Modulators
    • Here's How E-Commerce and Digital Pharmacies Expand Access to Branded and Generic Cough Formulations Across Emerging Markets
    • Combination Therapies for Cold and Cough Drive Market for Multi-Symptom Relief Medications with Antitussive Components
    • Rising Focus on Chronic Cough and Refractory Cough Conditions Supports Development of Specialized Prescription Therapies
    • Here's How Consumer Demand for Fast Relief and Palatable Formulations Fuels Innovation in Lozenges, Syrups, and Rapid-Dissolve Formats
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antitussive Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antitussive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Peripherally Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Peripherally Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Peripherally Acting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Centrally Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Centrally Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Centrally Acting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pain Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pain Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Pain Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cold Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cold Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Cold Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cough Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cough Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cough Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Tablets Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Tablets Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Tablets Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Syrup Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Syrup Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Syrup Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • JAPAN
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • CHINA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • EUROPE
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Antitussive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • FRANCE
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • GERMANY
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Antitussive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • INDIA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Antitussive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Antitussive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • AFRICA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030

IV. COMPETITION